TALIPEXOLE DIHYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H15N3S.2ClH
Molecular Weight	282.233
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DPQAXNSOFFYKDS-UHFFFAOYSA-N

InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H

HIDE SMILES / InChI

Description
Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	5.8 null [pKi]
Dopamine D3 receptor 91 Target ID: CHEMBL234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	7.0 null [pKi]
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.43 null [pKi]
Alpha-2b adrenergic receptor 27 Target ID: CHEMBL1942 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.09 null [pKi]
Alpha-2c adrenergic receptor 37 Target ID: CHEMBL1916 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.37 null [pKi]
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	6.48 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic schizophrenia 6 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8102551	Primary		Preclinical	Unknown Approved Use Unknown
Parkinson's disease 226 Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.	2001 Jan 12	11164378
Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models.	2002 Jan	11853125
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.	2003 Apr	12649387
Repeated administration of methamphetamine causes hypersensitivity of D2 receptor in rat ventral tegmental area.	2003 Aug 21	12873735
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.	2004 Oct 11	15473914
Drug treatment of Parkinson's disease.	2004 Sep	22033779
Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.	2006	16569938
alpha2-adrenoceptor agonists as nasal decongestants.	2007	16809058
Pharmacological modulation of dopaminergic brain activity and its reflection in spectral frequencies of the rat electropharmacogram.	2008	19142029
Mechanism of decongestant activity of alpha 2-adrenoceptor agonists.	2008	17869148
Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.	2008 Apr 30	18074382
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?	2008 Mar	17680806
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.	2008 Nov 19	18835264
Oxidative neurodegeneration is prevented by UCP0045037, an allosteric modulator for the reduced form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.	2009 Nov 5	20087465
The neuroprotective effect of talipexole from paraquat-induced cell death in dopaminergic neuronal cells.	2010 Dec	20673835
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.	2010 May	21209752
[Dopaminergic neuroprotection and reconstruction of neural network tiara].	2010 Oct	20930477

Patents

Sample Use Guides

In Vivo Use Guide

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells

Name

Type

Language

TALIPEXOLE DIHYDROCHLORIDE

Common Name

English

TALIPEXOLE HYDROCHLORIDE

Common Name

English

TALIPEXOLE DIHYDROCHLORIDE [MI]

Common Name

English

Talipexole hydrochloride [WHO-DD]

Common Name

English

TALIPEXOLE HYDROCHLORIDE [JAN]

Common Name

English

TALIPEXOLE HYDROCHLORIDE [MART.]

Common Name

English

TALIPEXOLE HCL

Common Name

English

Code System Code Type Description

CAS

36085-73-1